Groupama Asset Managment Invests $38.69 Million in Merit Medical Systems, Inc. (NASDAQ:MMSI)

Groupama Asset Managment bought a new position in shares of Merit Medical Systems, Inc. (NASDAQ:MMSI - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 400,000 shares of the medical instruments supplier's stock, valued at approximately $38,688,000. Groupama Asset Managment owned 0.69% of Merit Medical Systems as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of MMSI. Barclays PLC raised its holdings in shares of Merit Medical Systems by 305.4% during the third quarter. Barclays PLC now owns 112,727 shares of the medical instruments supplier's stock worth $11,142,000 after acquiring an additional 84,923 shares during the period. EULAV Asset Management lifted its holdings in shares of Merit Medical Systems by 400.0% in the fourth quarter. EULAV Asset Management now owns 115,000 shares of the medical instruments supplier's stock valued at $11,123,000 after purchasing an additional 92,000 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Merit Medical Systems by 85.6% during the third quarter. JPMorgan Chase & Co. now owns 575,946 shares of the medical instruments supplier's stock worth $56,921,000 after buying an additional 265,648 shares during the period. AMI Asset Management Corp grew its holdings in shares of Merit Medical Systems by 28.7% during the fourth quarter. AMI Asset Management Corp now owns 33,041 shares of the medical instruments supplier's stock worth $3,196,000 after buying an additional 7,367 shares in the last quarter. Finally, Redhawk Wealth Advisors Inc. acquired a new stake in Merit Medical Systems in the 4th quarter valued at approximately $800,000. Institutional investors own 99.66% of the company's stock.

Remove Ads

Merit Medical Systems Stock Performance

Shares of MMSI stock traded down $11.46 during trading on Friday, reaching $92.50. 2,000,794 shares of the company's stock were exchanged, compared to its average volume of 462,604. Merit Medical Systems, Inc. has a twelve month low of $70.70 and a twelve month high of $111.45. The firm's fifty day moving average price is $104.19 and its 200-day moving average price is $101.22. The company has a quick ratio of 3.82, a current ratio of 5.36 and a debt-to-equity ratio of 0.57. The stock has a market capitalization of $5.44 billion, a PE ratio of 45.34, a PEG ratio of 2.34 and a beta of 0.91.

Insider Buying and Selling at Merit Medical Systems

In related news, CFO Raul Jr. Parra sold 12,451 shares of the business's stock in a transaction on Friday, February 28th. The stock was sold at an average price of $98.81, for a total value of $1,230,283.31. Following the completion of the sale, the chief financial officer now directly owns 24,201 shares in the company, valued at $2,391,300.81. The trade was a 33.97 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Brian G. Lloyd sold 25,000 shares of the stock in a transaction on Friday, February 28th. The stock was sold at an average price of $99.50, for a total value of $2,487,500.00. Following the transaction, the insider now owns 38,993 shares in the company, valued at $3,879,803.50. The trade was a 39.07 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 109,132 shares of company stock worth $11,139,521 over the last ninety days. Insiders own 3.70% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on MMSI shares. Barrington Research decreased their price target on shares of Merit Medical Systems from $115.00 to $111.00 and set an "outperform" rating for the company in a research note on Wednesday, February 26th. Wells Fargo & Company lowered their price target on shares of Merit Medical Systems from $120.00 to $117.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. Needham & Company LLC reduced their price objective on shares of Merit Medical Systems from $122.00 to $116.00 and set a "buy" rating for the company in a research note on Wednesday, February 26th. Canaccord Genuity Group lowered their target price on Merit Medical Systems from $128.00 to $127.00 and set a "buy" rating on the stock in a research report on Wednesday, February 26th. Finally, JPMorgan Chase & Co. assumed coverage on Merit Medical Systems in a report on Friday, March 28th. They set an "overweight" rating and a $120.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $111.70.

Merit Medical Systems Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.